The cost effectiveness of reusable vs. single-use flexible bronchoscopy in the peri-operative setting has yet to be determined. We therefore aimed to determine this and hypothesised that single-use flexible bronchoscopes are cost effective compared with reusable flexible bronchoscopes. We conducted a systematic review of the literature, seeking all reports of cross-contamination or infection following reusable bronchoscope use in any clinical setting. We calculated the incidence of these outcomes and then determined the cost per patient of treating clinical consequences of bronchoscope-induced infection. We also performed a micro-costing analysis to quantify the economics of reusable flexible bronchoscopes in the peri-operative setting from a highthroughput tertiary centre. This produced an accurate estimate of the cost per use of reusable flexible bronchoscopes. We then performed a cost effectiveness analysis, combining the data obtained from the systematic review and micro-costing analysis. We included 16 studies, with a reported incidence of crosscontamination or infection of 2.8%. In the micro-costing analysis, the total cost per use of a reusable flexible bronchoscope was calculated to be £249 sterling. The cost per use of a single-use flexible bronchoscope was £220 sterling. The cost effectiveness analysis demonstrated that reusable flexible bronchoscopes have a cost per patient use of £511 sterling due to the costs of treatment of infection. The findings from this study suggest benefits from the use of single-use flexible bronchoscopes in terms of cost effectiveness, cross-contamination and resource utilisation.
Introduction
Flexible bronchoscopes allow visualisation of the nasopharynx, oropharynx, larynx, trachea and its subsequent divisions for diagnostic and therapeutic purposes. It is estimated that 500,000 bronchoscopic procedures are performed annually in the USA alone [1] .
The risk of transmission of infection following bronchoscopy with reusable flexible bronchoscopes is often under-considered, even when they are reprocessed according to infection control guidelines and recommendations [2] [3] [4] [5] .
However, the transmission of pathogenic organisms via contaminated reusable flexible bronchoscopes remains an evident risk [6] [7] [8] , even if appropriate decontamination procedures are adhered to [9] . There are unquantifiable risks of cross-contamination and infection from reusable flexible bronchoscopes, along with uncertainty regarding their cost effectiveness. Reusable flexible bronchoscopes are often used by anaesthetists to place tracheal tubes, either awake or asleep, and to check adequate positioning of double-lumen tubes. Therefore, cross-contamination risk will also apply to these patients.
Single-use flexible bronchoscopes are delivered sterile and thus should minimise the risk of infection transmission and cross-contamination compared with reusable flexible bronchoscopes. A previously reported cost effectiveness study of single-use flexible bronchoscopes in a typical intensive care unit (ICU) setting in the USA demonstrated that subsequent implementation is cost effective when looking at cross-contamination and potential subsequent infection, and it is associated with increased patient safety [10] . There are several reports of cross-contamination of reusable flexible bronchoscopes due to inappropriate cleaning, disinfection or lack of leak testing and drying [11, 12] . These reports do not provide a quantifiable risk for cross-contamination and subsequent infection, but it is accepted that there is a risk and cases are under-reported [8, [13] [14] [15] ; consequently, the literature lacks a quantified risk of cross-contamination and subsequent infection due to flexible bronchoscopy [8, 16, 17] . Moreover, several microcosting studies of reusable flexible bronchoscopes do not include costs of infections, which is why there is some uncertainty regarding these estimates [18] [19] [20] .
We therefore aimed to determine the cost per use and cross-contamination risk of reusable flexible bronchoscopes and to ascertain the cost effectiveness of single-use flexible bronchoscopes compared with reusable flexible bronchoscopes in various clinical settings. To achieve this we conducted a micro-costing analysis of flexible bronchoscope utilisation from a high-throughput tertiary centre [21] and a systematic review of the literature.
Our primary hypothesis was that single-use flexible bronchoscopes are equally or more cost effective than reusable flexible bronchoscopes.
Methods
The preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidance was adhered to in the conduct of the systematic review [22] . Given an evident risk of patient cross-contamination and infection with reusable flexible bronchoscopes [6, 8] The relationship was used to predict missing data points within these two variables. Once regression methods were applied, all studies were included for quantitative synthesis. The modelling approach was based on principles of good practice for decision analytic modelling in healthcare analyses [24] .
The cost perspective used in this analysis was a UK higher in patients undergoing thoracic or head and neck surgery [27] , which are the cohort of patients in whom flexible bronchoscopes are most commonly used. However, there are no data directly demonstrating bronchoscopeinduced cross-contamination or infection in these patients, as infection is often assumed to be multifactorial. We were therefore only able to use published data of infection and cross-contamination from the ICU or elective endoscopy or bronchoscopy population. The cost of the clinical outcome was estimated from the studies that were included according to the clinical manifestations that were reported in included studies, such as respiratory tract infection prophylaxis and therapy [28] [29] [30] [31] [32] [33] [34] [35] [36] and sepsis [33, 35] . In the cohort of patients of interest for this study, we considered ventilator-associated pneumonia, sepsis and communityacquired pneumonia as suitable outcomes. The average cost of ventilator-associated pneumonia was identified from a review of 28 US community hospitals to be £25,426
sterling per patient [37] . From a systematic review of hospital-related cost of sepsis, the treatment-related costs were identified as £27,123 sterling per patient [38] . The costs of inpatient and outpatient community-acquired pneumonia were estimated from > 28,000 communityacquired pneumonia episodes from a large US database study at £13,151 and £1948, respectively, per patient [39] .
The weighted average was defined as the treatment-related costs per patient infected. This value was imputed in the cost-effectiveness analysis. A summary of all costs and effect inputs for the cost-effectiveness analysis is presented in Table 1 .
Using the results from the literature review and the micro-costing analysis to compute the cost-effectiveness analysis, a base-case result was generated. Sensitivity analyses were undertaken to capture uncertainty within parameters and to provide sufficient insight to decision-makers. Uncertainty is captured through deterministic and probabilistic sensitivity analyses. One-way (univariate) sensitivity analyses were applied to all parameters in the model to test its robustness by examining the impact on the incremental cost effectiveness ratio. All cost parameters were varied by AE 50%. Considering the average period of an 8-month investigation across the 16 studies, the effect parameters were varied from a low value of 0% risk to a high value of 20% risk. A scenario analysis was conducted from a previous Delphi approach to the general risk of patient cross-contamination and infection [10] . Furthermore, the impact of the incremental cost-effectiveness ratio was observed by varying the amortisation period of capital investments related to bronchoscopy materials to 10 years from the previous 5 years.
The probabilistic sensitivity analysis quantifies the overall uncertainty within parameters using pre-specified distributions ( Table 1 ). The modality of the probabilistic sensitivity analysis was a second-order Monte Carlo simulation with 10,000 iterations of the mean incremental cost-effectiveness ratios. These 10,000 iterations were drawn up in a cost effectiveness scatterplot to represent the expected avoidance of infection risk using a single-use compared with reusable flexible bonchoscopes.
According to International Guidelines in Health
Economics, the mean is used as it is the only relevant measure for economic decision making [40] . In economic calculations, we aim to capture the uncertainty of the sample mean, that is, parameter uncertainty, rather than variability or heterogeneity, that is, stochastic variability.
The uncertainty in the expected mean is the standard error (SE) [40] . Consequently, we report all cost data as mean (SE). 
Results
We identified 890 citations, of which 12 were duplicates.
Seven additional studies were considered through handsearching of two review articles [7, 8] . Across numerous studies a non-quantifiable risk was identified , thus not fulfilling the inclusion criteria for the quantitative analysis. After screening based on title and abstract and full-text review, we identified 16 studies for quantitative analysis of the cross-contamination and infection risk ( Fig. 2) [12, [28] [29] [30] [31] [32] [33] [34] [35] [36] [63] [64] [65] [66] [67] [68] . The setting of these studies were patients who underwent bronchoscopy in a hospital intensive care or respiratory unit setting, or during bronchoscopy or endoscopy in the UK, USA, France, Spain, Australia or Taiwan ( Table 2 ). The study designs were prospective observational and retrospective studies, and the period of contamination and infection investigation of patients undertaken was from one to 23 months [30, 33] . From the included studies, the differentiation between a pre-existing infection and a flexible bronchoscope-related infection was determined using traditional bacterial recognition or more recent methods that examine the association of isolates at a molecular level ( Table 2) . In the Supporting Information (Data S1), a detailed overview and description are provided of all costs incurred, and the allocation keys that were employed to more accurately reflect reality.
In the cost-effectiveness analysis, we found reusable flexible bronchoscopes to have a mean (SE) cost per patient Varying cost inputs by AE 50% did not have a significant impact on the expected value of the incremental cost-effectiveness ratio, which varied from À£15,232 to À£5,778. From Fig. 3 , the cost parameter with the greatest impact on cost effectiveness is the cost of clinical outcome, whereas the parameter with the lowest impact is the reprocessing cost per use of a reusable flexible bronchoscope.
Considering the average of 8 months of investigation across the 16 studies of patient contamination and infection, one-way sensitivity results from the CEA and a scenario analysis is presented in Table 3 .
The probabilistic sensitivity analysis was indicative of a potential net savings to hospitals ranging from £34 to 577 sterling per use and eliminating the risk of infection of approximately 1.71-4.07% using single-use flexible bronchoscopes compared with reusable flexible bronchoscopes ( Fig. 4 ).
Discussion
This systematic review and cost-effectiveness analysis found There are two main strengths of this study, the first being the micro-costing analysis as the cost comparison between reusable and single-use equipment is complex.
Numerous overhead cost elements must be considered, and this study captures more than previous studies [18] [19] [20] .
The other main strength is the fact that this is the first study to identify risk of patient contamination and infection from the published literature. In general, cost analyses lack precision in terms of including all relevant overhead costs [18] [19] [20] . This is difficult may have a limited impact on our data. Moreover, the data we used on the published incidence of infection could be secondary to tracheal intubation rather than the use of a flexible bronchoscope. However, given that only 44 of the included patients with evidence of infection were in critical care settings, it is unlikely that the incidence of infection could be primarily attributed to non-bronchoscopic sources.
In conclusion, our systematic review has demonstrated that the risk of patient infection following bronchoscopy with reusable flexible bronchoscopes is significant, warranting a need for guidelines on reprocessing to be stricter to ensure greater patient safety [8, 9, 72] . The total cost per use of a reusable flexible bronchoscope was calculated to be £249. The cost per use of a single-use flexible bronchoscope was £220 sterling. When considering the risk of infection in the cost analysis, reusable flexible bronchoscopes have a mean cost per patient of £511 sterling and an associated risk of infection at 2.8%. The findings from this study suggest benefits of single-use flexible bronchoscopes in terms of cost effectiveness, crosscontamination and resource utilisation.
